Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460129 | 0.91 | NR1H4 (0.35) | SIRT2SIRT3SIRT1NR1H4MRGPRX4 | |
| SCHEMBL2464327 | 0.91 | LTA4H (0.37) | SIRT2SIRT3SIRT1 | |
| SCHEMBL2460569 | 0.90 | NR1H4 (0.35) | SIRT2SIRT3KMT2ASIRT1NR1H4 | |
| SCHEMBL2463557 | 0.90 | NR1H4 (0.49) | SIRT2SIRT3MEN1KMT2ASIRT1 | |
| SCHEMBL2460274 | 0.89 | SIRT2 (0.47) | SIRT2SIRT3SIRT1NR1H4 | |
| SCHEMBL2463238 | 0.88 | SIRT2 (0.41) | SIRT2SIRT3SIRT1NR1H4 | |
| SCHEMBL2458314 | 0.87 | HTR1A (0.39) | SIRT2SIRT3SIRT1NR1H4 | |
| SCHEMBL2457963 | 0.87 | MRGPRX4 (0.43) | SIRT2SIRT3SIRT1LMNANR1H4 | |
| SCHEMBL2456890 | 0.87 | MRGPRX4 (0.45) | LMNANPC1RAB9AMRGPRX4 | |
| SCHEMBL2459648 | 0.86 | MRGPRX4 (0.50) | NR1H4RAB9AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | claimed |
| JP-2007509060-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1675860-A2 | IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | claimed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| EP-1675860-A2 | IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | SIRT2 1144/4885SIRT3 881/4885MEN1 1004/4885 |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | IGF1R, IRS1, IGFBP1 | SIRT2 1144/4885SIRT3 881/4885MEN1 1004/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | SIRT2 1144/4885SIRT3 881/4885MEN1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.